A Phase 1b Study of ONT 10 and Varlilumab in Patients With Advanced Ovarian Cancer or Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2016
Price : $35 *
At a glance
- Drugs ONT 10 (Primary) ; Varlilumab (Primary)
- Indications Advanced breast cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors Cascadian Therapeutics
- 29 Mar 2016 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.
- 29 Mar 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 05 Nov 2015 Status changed from recruiting to discontinued, as per the Celldex Therapeutics Inc media release.